[CAS NO. 63585-09-1] Foscarnet sodium
PRODUCTS SPECIFICATIONS [63585-09-1]
DESCRIPTION [63585-09-1]
Overview
| MDL | MFCD00013973 |
|---|---|
| Molecular Weight | 191.95 |
| Molecular Formula | CNa3O5P |
| SMILES | O=P(O[Na])(O[Na])C(O[Na])=O |
2 Publications Citing Use of MCE
Summary
In Vitro
Foscarnet sodium (Trisodium phosphonoformate) inhibits Influenza A Victoria (IC 50 =29 μM), Influenza B HK (IC 50 =61 μM), and Avian myeloblastosis virus (IC 50 =5-8 μM),HSV-1, several strains (IC 50 =0.4-3.5 μM) [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
H 2 O : 60 mg/mL ( 312.58 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 5.2097 mL | 26.0485 mL | 52.0969 mL |
| 5 mM | 1.0419 mL | 5.2097 mL | 10.4194 mL |
| 10 mM | 0.5210 mL | 2.6048 mL | 5.2097 mL |
References
- [1] Manischewitz JF, et al. Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro.Antimicrob Agents Chemother. 1990 Feb;34(2):373-5.
- [2] Oberg B, et al. Antiviral effects of phosphonoformate (PFA, foscarnet sodium).Pharmacol Ther. 1982;19(3):387-415.
- [3] Hakki M, et al. Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy.Curr Hematol Malig Rep. 2020 Jan 24.
Synonyms